(HPG) axis, an integral regulator of spermatogenesis. Here we examine the impact of shift work on semen parameters and reproductive hormones in infertile men.
INTRODUCTION AND OBJECTIVES: Anabolic steroid (AS)
use is increasing, with a 6.4% lifetime abuse rate for males. Use of high doses of AS can manifest with a variety of adverse effects on multiple different organ systems. Specifically, AS impact the male reproductive system via central suppression of gonadotropins leading to decreased endogenous testosterone production, testicular atrophy, and impaired spermatogenesis. Despite the known contraceptive effect of androgens, spontaneous pregnancies while using AS are often reported within online communities of users. Therefore, our objective is to describe selfreported medication patterns and fertility rates in a population of anabolic steroid users.
METHODS: Nine bodybuilding forums were identified using Google search terms. After receiving permission from the websites, a link to an anonymous 49 item questionnaire was posted. Data was collected using Survey Monkey. Information collected included demographics, anabolic steroid use, ancillary medications, and fertility outcomes. Only men attempting to achieve a pregnancy while using testosterone and other AS constituted the cohort of the current study.
RESULTS: A total of 323 participants initiated the survey, of whom 97 (30%) met inclusion criteria. The majority of men were 25-44 years old (63.9%), married (75.5%) and Caucasian (88.7%). Ancillary drug use was common with only 5.2% denying drug use other than anabolic steroids. The most commonly reported ancillary drugs were antiestrogens (selective estrogen receptor modulators and/or aromatase inhibitors -89.7%) and sexual enhancement medications (68%). The overall fertility rate was 92.8% with 82.5% achieving pregnancy within one year. Only 13.5% sought fertility evaluation with treatment required in 8.3%. Age at initiation of anabolic steroid use, maximum dosage utilized, yearly duration of supplementation, and number of years using steroids were not associated with a prolonged duration to pregnancy or decreased rate of pregnancy CONCLUSIONS: Fertility rates are maintained in a population of AS users and are relatively equivalent to age-matched historical controls. This surprising finding may be related to the common use of washout periods, adjunctive medications (SERMs, AIs), and incomplete suppression of the hypothalamic pituitary testicular axis despite large doses of AS. The use of Tyrosine Kinase Inhibitors (TKI) in men with certain malignancies has in many cases improved the course of illness from rapidly fatal to a chronic disease requiring long-term treatment. However, very little has been published on TKI effects on male fertility despite the potential for significant risk to fertility. Many major organizations have guidelines advocating fertility preservation (FP) for all patients at risk of impaired fertility from cancer treatment, yet it is unclear how often men receiving TKI are counseled on the fertility risks of their oncologic treatments and the need for FP. We sought to identify potential barriers to accessing oncofertility care, assess baseline understanding of treatment-related infertility, and characterize reproductive expectations of men receiving TKI treatment.
METHODS: A retrospective cohort of men receiving TKI at UCSF completed a single detailed questionnaire. Cancer history, consultation with treating physician about the possible effects on fertility, obstacles to fertility preservation methods and satisfaction with treatment decisions were addressed.
RESULTS: Fifty-one patients receiving TKI participated in the study. The mean age was 46 years (range 21-72). Thirty-one (61%) had chronic myelogenous leukemia and 26 (51%) had received prior e274 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 treatment for cancer (11 surgery, 12 chemotherapy, 3 radiation). While 18 (36%) said they would like to have children in the future and 24 (46%) had some degree of concern that their cancer treatment might affect their fertility, 26 (51%) were not given any information about the fertility risks of TKI by their medical team, 30 (59%) were not able to discuss possible ways to protect their fertility, and 39 (76%) did not have the opportunity to discuss protecting their testicles from cancer treatments. Furthermore, 32 (63%) felt they had encountered some barrier to fertility care prior to receiving their cancer treatment, including 11 (22%) who were not provided a referral to a fertility specialist, and 14 (27%) who did not understand that the cancer treatment might affect their fertility. CONCLUSIONS: Nearly half of the patients surveyed worried about the reproductive risks of TKI, and most felt they had not received enough information about these risks. Furthermore, the majority of men experienced barriers to oncofertility care. These findings highlight the need for medical providers to take a proactive approach to discuss potential fertility risks in men on TKI.
Source of Funding: None

PD13-11 COST-EFFECTIVENESS OF FERTILITY PRESERVATION IN TESTIS CANCER PATIENTS
Kirven Gilbert*, Atlanta, GA; Ajay Nangia, Kansas City, KS; Akanksha Mehta, Atlanta, GA INTRODUCTION AND OBJECTIVES: Paternity is an important concern among young testicular cancer survivors. Despite this, some affected men elect not to cryopreserve sperm prior to undergoing cancer treatment, because of the perceived costs of cryopreservation and the perceived successes of assisted reproductive technology (ART). The goal of this study investigated the cost-effectiveness of sperm cryopreservation compared to fertility management after undergoing cancer therapy among men with testicular cancer.
METHODS: We performed a systematic search of the Pubmed database for the following variables: risk of azoospermia after orchiectomy, 2 year surveillance, chemotherapy, RPLND, and radiation therapy (RT); rate of natural conception after cancer therapy, rate of conception with the use of IUI, and IVF/ICSI. Costs of cryopreservation were based on costs published commercial sperm cryobank companies. A decision tree was constructed using the TreePlan add-in for Microsoft Excel (TreePlan Software, San Francisco, California). The cost-effectiveness outcome was determined by the overall weighted cost of a given management branch divided by that branch's likelihood of pregnancy. A sensitivity analysis was performed for the price of microTESE between $3,000 to $11,000 and banking for a range of 2 to 10 years.
RESULTS: Of the total 1,113 articles identified, 55 papers were pertinent to the study question, and included. Patients undergoing chemotherapy or active surveillance had the highest chance of azoospermia over a year after treatment, at 18%. The average cost of banking was $402 one time fee with an additional $343/year. In patients undergoing active surveillance, banking had a lower cost-per-pregnancy when storing for less than 4 years and microTESE was $9,000 or greater. Banking prior to chemotherapy is more cost-effective when banking for 6 or fewer years regardless of microTESE price. Patients receiving RPLND, banking was more cost-effective when banking for 4 or fewer years and the cost of microTESE was $7,000 or greater. Banking was more cost-effective when done for 8 or fewer years regardless of price in patients undergoing RT.
CONCLUSIONS: A large proportion of men have recovery of spermatogenesis following chemotherapy or RT for testicular cancer (82% and 94%, respectively). Nevertheless, sperm cryopreservation prior to chemotherapy or RT remains the most cost-effective strategy for fertility preservation, across a range of possible costs associated with surgical sperm retrieval and ART.
Source of Funding: Urology Care Foundation Research Scholars Award
PD13-12
"THE BACK-UP VASECTOMY REVERSAL." TESTICULAR SPERM EXTRACTION AT THE TIME OF VASECTOMY REVERSAL IN THE COUPLE WITH ADVANCED MATERNAL AGE: A COST-EFFECTIVENESS ANALYSIS James Craig*, Jeremy Myers, William Brant, Sara Lenherr, Salt Lake City, UT; Thomas Walsh, Seattle, WA; Joseph Alukal, New York, NY; Jim Hotaling, Salt Lake City, UT INTRODUCTION AND OBJECTIVES: Vasectomy is an effective family planning method; however 6% will request vasectomy reversal (VR). Average time to VR is 6-10 years after vasectomy with a female partner age of 31-37. VR alone is a cost effective method of regaining fertility; however, the presence and degree of advanced maternal age (AMA) in this population has not been well studied. We evaluated different management options to resume family building in a couple with prior vasectomy using a cost effectiveness analysis model. METHODS: A model-based cost-utility analysis was performed estimating the mean cost and quality adjusted life years (QALYs) in couples with infertility due to a male history of vasectomy and a female history of AMA over a 1 year time period. The model was constructed evaluating fertility outcomes on 3 surgical options for the male partner: VR, testicular sperm extraction (TESE), or combination VR with TESE. Separate models were then built stratifying for female partner age: <35, 35-37, 38-40, and >40 years. Model QALY estimates obtained from the literature were: 0.56 for an infertile couple and 0.63 for an infertile couple who becomes pregnant. Average patient charges for VR, TESE, and in vitro fertilization (IVF) were calculated from data supplied by high volume academic centers. TreeAge was utilized as the modeling software.
RESULTS: The surgical options for the male resulted in 4 fertility strategies: natural conception, IVF, failed natural conception followed by IVF, and failed IVF followed by natural conception. The table below lists the cost/QALY for the 4 different fertility strategies stratified by female age.
CONCLUSIONS: VR with natural conception is the most cost effective means of fertility in all age groups evaluated. The back-up VR (combination VR and TESE) was more cost-effective and had a better monetary benefit profile than IVF alone in the maternal age groups of <35, 35-37, and 38-40. In couples with maternal age >40 years, the relatively low per cycle success rate of either approach (VR and natural conception, TESE and IVF) shows that the opportunity to conceive naturally post VR in any non-IVF ovulatory cycle added greatly to the potential success without significantly increasing cost. The back-up VR approach allows for this unique opportunity.
